Pressmeddelande -

EISAI OPENS NEW MANUFACTURING AND PROCESS RESEARCH BASE IN INDIA

 

FOR IMMEDIATE RELEASE

No. 09-51

Eisai Co., Ltd.

 

Eisai Opens New Manufacturing and Process Research Base in India

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Hauro Naito) today announced the completion of construction of the Eisai Knowledge Centre, India, the Company’s new manufacturing and process research base in India. Eisai will advance preparations such as technical transfer, process validation, stability test, towards the full scale operations scheduled to start by the end of fiscal year 2010.

The new facility will be Eisai’s first base to integrate Active Pharmaceutical Ingredients (APIs) and formulation manufacturing and API process research functions on one site. Eisai has made a total investment of approximately five billion yen on a 50-acre campus in the Special Economic Zone at Jawaharlal Nehru Pharma City located in Visakhapatnam (Vizag), Andhra Pradesh in south India.

Eisai Knowledge Centre, India was built with the aim of creating a future global hub capable of ensuring a stable supply of high quality pharmaceutical products and achieving innovation in API synthesis processes that will provide the platform for producing such products. In addition to the manufacturing of APIs and formulations of its major products such as the Alzheimer’s disease treatment Aricept®, Eisai plans to conduct API process research and manufacture API and formulations of the company’s next generation global products. After the opening of the Eisai Knowledge Centre, India, the Company’s API production will be handled by this facility together with the Kashima plant, Eisai’s another manufacturing plant in Japan.

With the operation of the Eisai Knowledge Centre, India, Eisai will further promote its hhc (human health care) philosophy and will continue to contribute to increasing the benefits of patients and their families around the globe by ensuring a stable supply of high quality pharmaceutical products that meet the various needs of different countries and markets around the world.  

[Please refer to the following notes for the outline and images of the Eisai Knowledge Centre, India]

Contact:

Public Relations Department

Eisai Co., Ltd.

TEL: +81-(0)3-3817-5120


Notes to Editors

 

Outline of Eisai Knowledge Centre, India

 

Company Name: Eisai Pharmatechnology & Manufacturing Pvt. Ltd.

 

Location: Visakhapatnam (Vizag), Andhra Pradesh, India

 

President: Sanjit Singh Lamba

 

Site Area: Approximately 50 acres

 

Scope of Business: Manufacturing and research of Active Pharmaceutical Ingredients (APIs) and formulations.

 

No. of Employees: Approximately 100 (including 20 researchers) (as of November 30, 2009)

 

Products to be manufactured: APIs and formulations of Aricept, Myonal, and next generation global products

 

Production Capacity: (APIs) one billion tablets per year, (formulations) 30 tons per year




Main Entrance API Lab




API Building Formulation Building



Ämnen

  • Ekonomi, finans

Kategorier

  • eisai
  • epilepsi
  • epilepsiguiden.net
  • epileptiskt anfall
  • inovelon
  • neurobloc
  • neurologi
  • pariet
  • prialt
  • zebinix
  • zonegran

 JapanEisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care forthehealth and well-being of people worldwide. We combine our talents to understand and meet the needs ofpatients and their families to enhance the quality of life.

Kontakter

  • EISAI OPENS NEW MANUFACTURING AND PROCESS RESEARCH BASE IN INDIA
    EISAI OPENS NEW MANUFACTURING AND PROCESS RESEARCH BASE IN INDIA
    Licens:
    All rights reserved
    Filformat:
    .pdf
  • EISAI - WHEN EAST MEATS WEST...
    EISAI - WHEN EAST MEATS WEST...
    Licens:
    All rights reserved
    Filformat:
    .pdf

Relaterat innehåll

  • GLOBAL PHASE III STUDY RESULTS SHOW ERIBULIN MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL

    FOR IMMEDIATE RELEASE
    No. 09-46
     
    Eisai Co., Ltd.
     


     
     
    Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin mesylate, "eribulin"), discovered and developed by the Company, in patients with locally advanced or metastatic breast cancer.

  • BANEBRYDENDE ANTIEPILEPTIKUM LANCERES I DANMARK

    Den store andel af epilepsipatienter, der stadig får anfald trods medicinsk behandling, får nu en ny mulighed for at nedbringe deres anfaldsfrekvens. En ny tillægsbehandling Zebinix (eslicarbazepinacetat) til voksne patienter med partielle anfald giver således mulighed for nedsat anfaldsfrekvens og forhøjet livskvalitet med én pille om dagen.

  • Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects

    A subsidiary of Eisai Corporation of North America, Morphotek®, Inc., today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumb in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

  • NOVEL ONCE DAILY ANTI-EPILEPTIC ZEBINIX® APPROVED IN THE EUROPEAN UNION



    - NEW OPTION FOR TREATMENT OF EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES
    Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis Portela), and Eisai Europe Limited (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), today announced that the novel once daily anti-epilept

  • EISAI PÅ VÄG ATT BLI EN AV DE LEDANDE INOM EPILEPSIOMRÅDET

    Eisai och Bial tillkännager samarbetsavtal gällande marknadsföring i Europa av Zebinix, ett nytt medel mot epilepsi. Detta är en unik möjlighet... och ger Eisai en ledande ställning inom terapiområde epilepsi, säger Christer Ahlberg, VD för Eisai i Norden. (Läs mer i bifogad pressrelease.)

  • EISAI - KRAFTIG TILLVÄXT MED MÄNNISKAN I FOKUS

    För fyra år sedan etablerade sig det japanska läkemedelsföretaget Eisai i Norden. Idag, 25 anställda och sju produkter senare, är namnet välkänt i branschen, framförallt för sina preparat mot epielpsi och alzheimer. Nu väntar nästa steg i företagets tillväxtplan - en storsatsning på onkologi...

  • Läkemedelsföretaget Eisai satsar stort i Europa

    Läkemedelsföretaget Eisai - med nordiskt huvudkontor i Stockholm - har satsat 100 miljoner Euro i ett stort projekt ,som kommer att skapa 500 nya arbetstillfällen inom forskning och utveckling, samt tillverkning i Hatfield Business park, nära London...